Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2017-03-30 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2016年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2016 by 福安药业（集团）股份有限公司. It details the proposed cash dividend per share and capital reserve conversion to shares, including the total shares before and after the distribution. The document mentions the board of directors' approval and that the plan requires shareholder meeting approval. The document length is short (912 characters), and it is an announcement of a profit distribution plan, not the full annual report or financial statements. This fits the category of Notice of Dividend Amount (DIV), as it announces dividend amounts and related details for shareholders.
2017-03-30 Chinese
2016年度控股股东及其他关联方占用资金情况专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) concerning the 2016 year-end situation of funds occupied by controlling shareholders and related parties of 福安药业（集团）股份有限公司. It is issued by an accounting firm and references the audit of the company's 2016 financial statements. The content includes a detailed summary table of fund occupation by related parties and states that it is prepared according to regulatory requirements from the China Securities Regulatory Commission and the State-owned Assets Supervision and Administration Commission. The document is a standalone audit report focusing on a specific regulatory compliance issue related to related-party fund occupation, not a full annual report or interim report. It does not contain full financial statements but is an audit report on a specific matter. The document length is about 2138 characters, which is relatively short but contains substantive audit content. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2016
2017-03-30 Chinese
2016年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2016年度监事会工作报告" which translates to "2016 Supervisory Board Work Report". It details the supervisory board's activities, meetings, and oversight of the company's operations, financial status, internal controls, and compliance with laws during the 2016 fiscal year. It includes summaries of meetings, opinions on company operations, financial audits, fundraising management, and internal controls. The document is a detailed report on the supervisory board's work rather than an announcement or a brief summary. It does not fit categories like Annual Report (10-K) or Interim Report (IR) because it focuses on supervisory board activities and oversight rather than full financial statements or management discussion. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content and is not merely an announcement. The best fitting category is Audit Report / Information (AR) because it includes audit opinions, supervisory board oversight of financial and operational matters, and internal control evaluations, which align with the description of standalone audit reports and related supervisory information. FY 2016
2017-03-30 Chinese
独立董事2016年度述职报告（黎明）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2016 by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on various board matters, committee work, investigations, and efforts to protect investor rights. The content focuses on governance, oversight, and director duties rather than financial results or audit opinions. It is a report by a board member about their role and activities, which fits the category of Board/Management Information (MANG). The document length is 2612 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification. Therefore, the best classification is MANG with high confidence.
2017-03-30 Chinese
2016年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2016 年年度报告全文" which translates to "2016 Annual Report Full Text" for 福安药业（集团）股份有限公司 (Fuan Pharmaceutical Group Co., Ltd.). It contains detailed financial data, including revenue, net profit, asset totals, and quarterly financial indicators. It also includes sections such as company overview, business summary, management discussion and analysis, risk factors, governance, and financial statements. The length is substantial (15,000 characters), and the content is comprehensive, covering the full scope of an annual report rather than just an announcement or summary. There is no indication that this is merely a report publication announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2016
2017-03-30 Chinese
关于烟台只楚药业有限公司2016年度业绩承诺实现情况的说明之审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by Beijing Yongtuo Certified Public Accountants on the performance commitment realization of Yantai Zhichu Pharmaceutical Co., Ltd. for the year 2016. It includes the auditor's responsibility, management's responsibility, audit opinion, and detailed financial performance data related to the asset acquisition and performance commitments. The document references compliance with the China Securities Regulatory Commission's rules on major asset restructuring and contains an auditor's opinion on the fairness of the performance commitment realization. It is not a full annual report or interim report but a standalone audit report related to a specific matter (performance commitment realization). Therefore, it fits the category of Audit Report / Information (AR). The document length is about 4881 characters, which is sufficient to contain substantive audit content rather than a mere announcement or certification letter. Hence, the classification is AR with high confidence. FY 2016
2017-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.